Summary In order to unravel possible mechanisms of clinical resistance to topoisomerase inhibitors, we developed a topotecan-resistant human IGROV-1 ovarian cancer cell line, denoted IGROVTlOOr, by stepwise increased exposure to topotecan (TPT). The IGROVT100r cell line was 29-fold resistant to TPT and strongly cross-resistant to . However, the IGROVTlOOr showed only threefold resistance to camptothecin (CPT). Remarkably, this cell line was 32-fold resistant to mitoxantrone, whereas no significant cross-resistance against other cytostatic drugs was observed. No differences in topoisomerase protein levels and catalytic activity as well as topoisomerase cleavable complex stabilization by CPT in the IGROV-1 and IGROVTIOOr cell lines were observed, indicating that resistance in the IGROVTlOOr cell line was not related to topoisomerase I-related changes. However, resistance in the resistant IGROVTlOOr cell line to accompanied by decreased accumulation of the drugs to approximately 15% and 36% of that obtained in IGROV-1 respectively. No reduced accumulation was observed for CPT. Notably, accumulation of TPT in the IGROV-1 cell line decreased under energy-deprived conditions, whereas the accumulation in the IGROVTlOOr cell line increased under these energy-deprived conditions. The efflux of TPT at 370C was very rapid in the IGROV-1 as well as the IGROVT100r cell line, resulting in 90% efflux within 20 min. Importantly, the efflux rates of TPT in the IGROV-1 and IGROVTlOOr cell lines were not significantly different and were shown to be independent on P-glycoprotein (P-gp) or multidrug resistance-associated protein (MRP). These results strongly suggest that the resistance of the IGROVTlOOr cell line to TPT and SN-38 is mainly caused by reduced accumulation. The reduced accumulation appears to be mediated by a novel mechanism, probably related to impaired energy-dependent uptake of these topoisomerase drugs.
DNA topoisomerase I (topo I) catalyses changes in DNA topology through cycles of transient DNA strand breaks and religations (Wang, 1985; Garg et al, 1987; Liu, 1989) . During these events, a covalent complex, the so-called cleavable complex, is formed. Topo I-inhibiting anti-cancer agents, e.g. camptothecin (CPT) are capable of stabilizing the cleavable complex formed by topo I, and inhibit the DNA function of topo I (Gallo et al, 1971; Hsiang et al, 1985; Hsiang et al, 1989) . Drug treatment results in inhibition of DNA replication and chromosomal fragmentation. Because of practical and clinical problems associated with CPT, a number of derivatives have been developed in recent years, e.g. irinotecan and its active metabolite SN-38, TPT, 9-aminocamptothecin (9-AC) and GI-147211 (Sinha, 1995) . These drugs show a broad spectrum of anti-cancer activity in preclinical and clinical studies (Giovanella et al, 1989; Rowinsky et al, 1992; Slichenmyer et al, 1993; Potmesil, 1994; Rowinsky et al, 1994; Tanizawa et al, 1994; Sinha, 1995; Conti et al, 1996) . However, tumours may develop clinical resistance against these topo I inhibitors. For this reason, studies on the mechanisms of resistance to topo I inhibitors are warranted.
Several topo I inhibitor resistant cell lines have been established (Andoh et al, 1987; Eng et al, 1990; Kanzawa et al, 1990; Sugimoto et al, 1990; Hendricks et al, 1992; Madelaine et al, 1993; Pantazis et al, 1994; Fujimori et al, 1995; Sorensen et al, 1995) . The mechanism of resistance has often been ascribed to various topo I-related changes, e.g. (1) reduced topo I catalytic activity (Madelaine et al, 1993; Fujimori et al, 1995; Sorensen et al, 1995) , (2) decreased formation of cleavable complexes (Madelaine et al, 1993; Fujimori et al, 1995) , (3) decreased expression of topo I (Eng et al, 1990; Sugimoto et al, 1990) and (4) a point mutation or rearrangement of topo I genes (Andoh et al, 1987; Fujimori et al, 1995) . Reduced accumulation of TPT, due to P-glycoprotein (Pgp) overexpression, has been reported to add to resistance to topo I inhibitors as well Mattern et al, 1993; Hasegawa et al, 1995) . Moreover, TPT is also a substrate for the multidrug resistance-associated protein (MRP) (Maliepaard et al, 1996) . Importantly, resistance to CPT does not appear to be related to P-gp or MRP Mattem et al, 1993; Maliepaard et al, 1996) . This difference between TPT and CPT may be partly caused by positive charge of TPT at physiological pH, although other factors may also be important in this respect (Mattern et al, 1993) .
In this paper, we report the development and characterization of a TPT-resistant human IGROV-1 ovarian cancer cell line that is highly cross-resistant to SN-38, but displays only minor resistance to CPT. The acquisition of resistance was associated with reduced cellular accumulation rather than changes of topo I catalytic activity or cleavable complex formation. This reduced accumulation was shown to be independent of P-gp or multidrug resistanceassociated protein (MRP). Because of these characteristics, this cell line appears to be a valuable model for studying the mechanisms of resistance to topo I inhibitors.
MATERIALS AND METHODS Chemicals and drugs
CPT was obtained from Aldrich (Bornem, Belgium) . TPT (Basingstoke, UK) . Bovine calf serum (BCS) was purchased from Hyclone (Logan, Utah, USA) and the actin monoclonal antibody (MAb) from Boehringer Mannheim (Almere, The Netherlands). The P-glycoprotein-specific MAb C219 was obtained from Cis Biointemational (Gif-sur-Ivette, France) and the MRP-specific MAb MRPrl was kindly provided by Dr R Scheper (Flens et al, 1994 ) (Department of Pathology, Free University, Amsterdam).
Cell lines and development of resistance
The human ovarian cancer IGROV-1 and the TPT-resistant IGROVT,OOr cells were cultured in Hepes-buffered RPMI 1640 medium, supplemented with 10% Bovine Calf Serum (BCS), 10 mm sodium bicarbonate, 2 mM glutamine, gentamycin, penicillin, streptomycin and phenol red in a humidified atmosphere of 5% carbon dioxide at 37°C. The TPT-resistant IGROVTIM cell line was developed by continuous exposure to TPT. The starting concentration of TPT used for incubation was 12 nM (5 ng ml-'). Fresh medium, containing TPT, was added every week. The TPT concentration was increased stepwise to 24, 48, 96 and finally to 235 nrm after 5 months of culturing. The cells were passaged at 235 nm TPT for another 4 months, after which TPT was withdrawn. No change in TPT resistance was observed after withdrawal of TPT for at least 3 months. The cells were frequently monitored for mycoplasma contamination, using the Hoechst 33258 dye colouring method.
Assessment of cytotoxicity and cross-resistance The cytotoxicity of TPT, SN-38, CPT, DOX, VP-16, CDDP, paclitaxel, 5-FU, MX and MTX against the IGROV-1 and IGROVT,OOr cells was estimated using the SRB assay (Skehan et al, 1990) . Stock solutions of TPT (1.0 mg ml-') were prepared in Millipore water. SN-38 and CPT were dissolved in dimethyl sulphoxide (DMSO) at a concentration of 1.0 mg ml-', whereas DOX, VP-16, CDDP, 5-FU, MX and MTX were dissolved in 0.9% sodium chloride (at concentrations of 2.0, 20, 1.0, 50, 2.0 and 2.5 mg ml-' respectively). Paclitaxel was applied as the clinical formulation Taxol, i.e. dissolved at a concentration of 6.0 mg ml-1 in EtOH/Cremophor EL 1:1. All drugs were diluted in RPMI medium just before the start of the incubation. TPT, SN-38 and CPT were prediluted twofold with 0.1% acetic acid to convert the compounds into their active lactone form. Cells (2 x 103 cells per well) were plated in 96-well plates and pre-incubated for 48 h at 37°C. On day 2, serial threefold dilutions of drug were added, yielding concentrations ranging from 0.08 ng ml-' to 500 ng ml-', or 2.1 to 13 500 ng ml', depending on the IC50 -values observed in pilot experiments, and cells were incubated for 5 days. Subsequently, cells were fixed with 10% trichloroacetic acid and put at 4°C for 1 h. After thorough washing with water, the cells were stained for at least 15 min with 0.4% sulforhodamine B (SRB), dissolved in 1% acetic acid. After this incubation period, the cells were washed with 1% acetic acid to remove unbound stain. The plates were air dried, and the bound protein stain was dissolved in 150 gl of 10 mm Tris buffer, pH 7.3. Absorbance was read at 540 nm, using a Model 450 Microplate reader (Bio-Rad Laboratories, CA, USA).
P-gp and MRP expression
Immunocytochemical detection of P-gp and MRP was performed according to previously used procedures (Sonneveld et al, 1992; Nooter et al, 1995) . Cytospin preparations were fixed in cold acetone (10 min, 0C), air dried and incubated with the MRPspecific MAb MRPrl or with the P-gp-specific MAb C219. Antibody binding was detected using alkaline phosphatase-conjugated immunoglobulin (Dako, Copenhagen, Denmark) and alkaline phosphatase substrate using new fuchsine (Dako). The slides were counterstained with haematoxylin and mounted. The specificity of C219 and MRPrl has been documented in detail elsewhere (Grogan et al, 1990; Flens et al, 1994) . Before use, C219 and MRPrl were diluted (1:10 and 1:1500 respectively) in Trisbuffered saline (50 mm Tris pH 7.4) containing normal rabbit serum (10%, w/v), normal goat serum (1%, w/v) and normal human AB serum (1%, w/v). Each assay included the use of an isotype-matched irrelevant MAb (mouse IgG2a and rat IgG2a, respectively, for C219 and MRPrl).
Topo I protein levels and catalytic activity IGROV-1 and IGROVTI,Or cells in logarithmic growth were harvested and denatured in 62.5 mm Tris, 10% glycerol, 2.5% sodium dodecyl sulphate (SDS), 5% 3-mercaptoethanol, 0.005% bromophenol blue and 0.5 mg ml-1 Pefablock, at 100°C for 5 min.
After separation of the proteins on a 10% polyacrylamide gel, proteins were electrophoretically transferred to PVDF immubolin membranes (Millipore, Bedford, MA, USA). Proteins were hybridized using topo I and actin antibodies. Actin was included as control for protein loading for each sample. Spots were quantitated using a phosphor imaging system (Fujix Bas 2000) .
Nuclear extracts were prepared as described (van der Zee et al, 1991) . Topo I catalytic activity in these nuclear extracts was assayed by monitoring the relaxation of supercoiled pBR322 DNA (250 ng) (Liu and Miller, 1981) . Samples were analysed by electrophoresis on a 1% agarose gel. After staining the gels with British Journal of Cancer (1998) 77(10), [1645] [1646] [1647] [1648] [1649] [1650] [1651] [1652] . Cancer Research Campaign 1998
Novel mechanism of topotecan resistance 1647 Cells were incubated with TPT for 5 days. Cytotoxicity of TPT was assessed using the SRB assay, as described in Materials and methods (Hsiang et al, 1985) . The reaction mixtures contained the lowest amount of nuclear proteins that was able to yield complete relaxation of 250 ng of pBR322 DNA. Reaction products were separated on 1% agarose gel and visualized as described above. Each experiment was performed in triplicate. (Bradford, 1976) . The concentration of TPT in the sample was measured using a previously described sensitive high-performance liquid chromatography (HPLC) method . Topo I inhibitors, such as TPT, exist in equilibrium between the lactone and the hydroxy-acid form (Beijnen et al, 1990) , of which the lactone is the active form. The equilibrium between the TPT lactone and the hydroxy-acid form is pH dependent. At pH 7.5, eventually, approximately 90% of total TPT will be in the hydroxy-acid form, whereas, at pH 5.0, this is only approximately 10%. Preliminary experiments showed that in cell-free medium, at pH 7.5 and 37°C, after 30, 60 and 90 min of incubation of TPT (lactone), approximately 25%, 45% and 60% of the lactone was converted to the hydroxy-acid form respectively. As the hydroxyacid is not taken up in the cells, the interconversion could influence the uptake data for TPT. For this reason, we used a relatively short incubation period of 30 min in all our experiments. This procedure yields approximately 75% of TPT still in the lactone form at the end of the incubation, as was confirmed by the abovementioned HPLC analyses. Only small fluctuations in the pH of the medium were noted in the incubation experiments (the pH was below pH 8 in all cases), and these pH differences did not affect the exposure of the cells to TPT in its lactone form within the given exposure time. The accumulation process of TPT in the IGROV-1 and IGROVT,a,, cell lines was also studied at0°C. The parental and resistant cell lines were incubated for 30 min at0°C with 0.95 or 1.90 gM TPT. After this incubation, samples were treated as described above.
The influence of the P-gp-blocking agent VPL on the accumulation of TPT in the IGROV-l and resistant IGROVTl00 cell lines was evaluated by incubating the cells for 30 min simultaneously with 1.90 ,M TPT and 1O ,M VPL. The effect of glutathione depletion on the MRP-mediated efflux (Versantvoort et al, 1995; Zaman et al, 1995) 470 nm and 3.55 ,UM, respectively, resulting in similar intracellular concentrations of the drug. After exposure to TPT, cells were washed twice with PBS at 37°C, resuspended in 4 ml of prewarmed drug-free RPMI medium and incubated at 37°C. In order to determine the efflux kinetics of TPT, flasks were withdrawn directly after the washing procedure and after 5-, 10-and 20-min incubation in drug-free medium. Cells were washed with PBS, harvested and the intracellular concentration of TPT at these time-points was determined as outlined above. The experiment was also performed at 0°C. In this experiment, cells were loaded with TPT at 370C as described above, subsequently washed with ice-cold PBS and incubated further at 0°C. The intracellular concentration of TPT was determined directly after the washing procedure and after a 10-min incubation in drugfree medium. (Versantvoort et al, 1992) . This procedure resulted in a decreased intracellular concentration of ATP to approximately 10% of the original concentration.
After this energy-depleting step, TPT (1.90 gM) was added to the energy-depleted medium, and cells were incubated at 370C for 30 min. Samples were analysed as described above.
Energy dependence of efflux
The energy dependence of TPT efflux from the IGROV-1 and IGROVTIOOr cell lines was studied by incubating these cells, which had been transferred 15 min before incubation to the above- 
Expression of P-gp and MRP1
Using immunocytochemistry, no expression of P-gp was noted in the resistant IGROVTlOO and parental cell lines (Figure 2 ). About 20% of the IGROVTlOOr and 10% of the IGROV-1 cells stained for mainly cytoplasmic MRP1 (Figure 2 ). MRP1-mediated staining in these cell lines was very weak, compared with the staining that was observed in the MRP1-overexpressing GLC4/ADR cell line (Zaman et al, 1993) , which was used as positive control.
Topo I protein levels, catalytic activity and stabilization of topo I cleavable complex by CPT Western blots of topo I in the IGROV-1 and IGROVTI,, cells are shown in Figure 3 . No significant differences in topo I levels between IGROV-1 and IGROV Tl1 were observed. Furthermore, no apparent differences in topo I catalytic activity was observed between the two cell lines (Figure 4 ). In both cell lines, topo I-mediated relaxation of The accumulation of SN-38 in the IGROVTIOOr cell line was decreased to 36% of that in the IGROV-1 (Table 2) . However, no decreased accumulation was observed for CPT in the resistant IGROVTlOOr cell line.
Effects of VPL and BSO on the cellular accumulation of TPT
In order to investigate whether reduced TPT accumulation was mediated through MDR-related P-gp or MRP1, cells were treated with the P-gp-blocking agent VPL (10 jM) or glutathionedepleting BSO (50 jM). Simultaneous incubation of TPT with 10 jM VPL did not significantly influence the intracellular accumulation of TPT in the IGROV-1 or IGROVTIOOr cell lines (Table   3 ), demonstrating that P-gp is not involved in the reduced accumulation of TPT in the IGROVTIOOr cell line. Also MRP1 is not the major cause of reduced accumulation, as depletion of glutathione by a 24-h preincubation of the IGROVTIOO with BSO affected the accumulation of TPT only to a limited extent (Table 3) . (0) Notably, accumulation of TPT in the GLC4/ADR cell line, which was used as positive control for MRP expression, was reduced to only approximately 69% of the accumulation in the parental GLC4 (Table 3 ). In the GLC4/ADR cell line, accumulation was completely restored upon incubation with BSO. This finding supports the conclusion that MRP overexpression in the Accumulation and efflux at lower temperature In order to assess the role of active transport in the kinetics of TPT, accumulation and efflux of TPT were assayed at 0°C. As shown in Figure 8 , the efflux of TPT from the parental IGROV-1 and IGROVTI,0, cells was completely inhibited in preloaded cells by lowering the temperature to 0°C. Data on the accumulation of TPT (1.90 jM) at 370C and 0°C are shown in Figure 9 . At 0°C, accumulation in the parental IGROV-I cell line was only 7.3% of the accumulation at 370C (P < 0.001). In the IGROVTI, cell line, accumulation at 0°C was lowered to approximately 50% of its value at 37°C. British Journal of Cancer (1998) 
DISCUSSION
We developed the TPT-resistant human IGROVTlOOr ovarian cancer cell line, which is cross-resistant to SN-38 but displays only minor resistance to CPT. Resistance to these CPT analogues has been attributed to reduced expression or reduced activity of topo I (Eng et al, 1990; Sugimoto et al, 1990; Madelaine et al, 1993; Fujimori et al, 1995) Multidrug resistance has been associated with an increased expression of P-gp and MRP1, yielding reduced intracellular accumulation of drugs. P-gp has been shown to be involved in resistance to TPT, as acquired resistance to TPT was accompanied by increased expression of P-gp and reduced accumulation . However, in the IGROVTIM cell line, no overexpression of P-gp was observed. Furthermore, no P-gp-related MDR characteristics are present in the IGROVTm cell line, as no cross-resistance to other drugs except MX is observed. Also the absence of a stimulating effect of VPL on accumulation of TPT in this cell line argues against the involvement of P-gp in the mechanism of resistance of TPT and SN-38. Also MRP1, which is expressed in about 20% of the resistant cells, does not appear to be critical in relation to the acquired reduced accumulation and resistance in the IGROVT100,. cell line, as the cell line does not show an MDR phenotype (Table 1) . Moreover, inhibition of MRP1 by depletion of glutathione does not result in complete reversal of the reduced accumulation of TPT in the IGROVTI00r cells.
We propose that our data are consistent with the hypothesis that an energy-dependent influx system for TPT and SN-38 is present in the IGROV-l cell line but is defective in the IGROVTIM cell line. The following points support this hypothesis. The efflux of TPT from the IGROV-1 as well as the IGROVTlIt cells was completely inhibited by lowering the temperature to 0°C. Lowering of the temperature also resulted in the almost complete inhibition of the accumulation of TPT in the IGROV-1 cell line.
However, accumulation of TPT in the resistant IGROVTIOOr cell line was decreased to a lesser extent at 0°C, compared with accumulation at 37°C in this cell line. This indicates that in the IGROVT,OOr a significant portion of TPT apparently accumulates by temperature-independent, and therefore presumably energyindependent, processes, whereas in the IGROV-1 a major part of TPT is accumulated by temperature-dependent processes.
Strikingly, the accumulation of TPT at 0°C was similar in both cell lines. The energy dependence of TPT accumulation in the IGROV-1 cell line was further indicated by the energy depletion experiment, which yielded a decreased accumulation of TPT in the IGROV-1 cell line. However, accumulation of TPT in the IGROVTIOOr cell line under energy-deprived conditions was increased. As efflux characteristics of TPT in the IGROV-1 and IGROVTift cell lines are not significantly different, the difference in intracellular accumulation may be explained by an energydependent inward transport system in the IGROV-l cell line that is capable of transporting TPT and SN-38 but, however, is not able to transport CPT. Probably such a system is hampered in the IGROV Tlft cell line. This mechanism of resistance to topotecan and SN-38 has not been described before. However, for other drugs, i.e. the vinca alkaloids, energy-dependent influx has been observed (Sirotnak et al, 1986) . Furthermore, abrogation of that uptake route was shown to result in resistance to, for example, vincristine (Sirotnak et al, 1986) . Recently, Yang et al (1995) reported an MX-resistant breast carcinoma MCF7 cell line that, surprisingly, displayed a selective cross-resistance against TPT and SN-38, but lacked resistance to CPT (Yang et al, 1995) . Although no data are available concerning the accumulation of these CPT derivatives in this MCF7 cell line, the similar cross-resistance patterns in this MCF7/MX and our IGROVTlO, cell line suggest that the resistance in these cell lines is mediated by the same type of mechanism.
In conclusion, we developed a TPT-resistant IGROV-1 human ovarian tumour cell line that displays significant cross-resistance to SN-38, but is only marginally resistant to CPT. The resistance is accompanied by decreased accumulation of TPT and SN-38, and is not mediated by P-gp or MRP1. The net energy-dependent efflux of TPT in the IGROV-1 and IGROVTIO,, cell lines was not significantly different. In addition, no significant differences have been observed between energy-independent efflux of TPT in the parental and the resistant cell line. We hypothesize that the resistance to TPT in the IGROVTlO is caused by reduced influx. In our laboratory, work has started that is aimed at a further characterization of this accumulation defect of TPT and SN-38 in the IGROVTIOOr cell line.
